ReviewCancers2015
Molecular Targeted Intervention for Pancreatic Cancer.
Review in Cancers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Herbals and Plants in the Treatment of Pancreatic Cancer: A Systematic Review of Experimental and Clinical Studies.Nutrients · 2022Pooled it
- Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial.Journal of the National Cancer Institute · 2018Trial
- Bile Acids in Pancreatic Carcinogenesis.Metabolites · 2024Review
- Triple targeting of mutant EGFRJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Anticancer effects of herbal medicines in pancreatic ductal adenocarcinoma through modulation of steroid hormone response proteins.Scientific reports · 2022Article
- Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Neuroprotective Potential of Berberine Against Doxorubicin-Induced Toxicity in Rat's Brain.Neurochemical research · 2021Article
- Fasting to enhance Cancer treatment in models: the next steps.Journal of biomedical science · 2020Review
- Article
- Role of Gene Therapy in Pancreatic Cancer-A Review.Cancers · 2018Review
- Emerging trends in the immunotherapy of pancreatic cancer.Cancer letters · 2018Review
- Disorders noticed during development of pancreatic cancer: potential opportunities for early and effective diagnostics and therapy.Central-European journal of immunology · 2017Review
- Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements.BioMed research international · 2017Review
- Human pancreatic cancer progression: an anarchy among CCN-siblings.Journal of cell communication and signaling · 2016Article
- LncRNAs in pancreatic cancer.Oncotarget · 2016Review
- HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.Molecular cancer research : MCR · 2016Article
- PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice.American journal of cancer research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Pancreatic cancer (PC) remains one of the worst cancers, with almost uniform lethality. PC risk is associated with westernized diet, tobacco, alcohol, obesity, chronic pancreatitis, and family history of pancreatic cancer. New targeted agents and the use of various therapeutic combinations have yet to provide adequate treatments for patients with advanced cancer. To design better preventive and/or treatment strategies against PC, knowledge of PC pathogenesis at the molecular level is vital. With the advent of genetically modified animals, significant advances have been made in understanding the molecular biology and pathogenesis of PC. Currently, several clinical trials and preclinical evaluations are underway to investigate novel agents that target signaling defects in PC. An important consideration in evaluating novel drugs is determining whether an agent can reach the target in concentrations effective to treat the disease. Recently, we have reported evidence for chemoprevention of PC. Here, we provide a comprehensive review of current updates on molecularly targeted interventions, as well as dietary, phytochemical, immunoregulatory, and microenvironment-based approaches for the development of novel therapeutic and preventive regimens. Special attention is given to prevention and treatment in preclinical genetically engineered mouse studies and human clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.